logo-loader
HealthPharma & Biotech
Iovance Biotherapeutics

Iovance Biotherapeutics rides high after FDA grants Breakthrough Therapy designation for its cervical cancer treatment

Meanwhile, Baird reiterated its Outperform rating and $34 price target on the shares

magnifying glass over 'cancer'
LN-145 treats cervical cancer in patients who have progressed to or past chemotherapy

Iovance Biotherapeutics Inc (NASDAQ:IOVA) stock jumped after the company announced Wednesday that its cervical cancer drug received Breakthrough Therapy designation from the Food and Drug Administration.

The move was accompanied by a note from Baird analyst Madhu Kumar, who reiterated an Outperform rating and $34 price target on the shares, which is more than double the biotech’s Wednesday close.

Shares jumped at Thursday's open but have since cooled, recently trading 2.3% higher to $17.

READ: Iovance Biotherapeutics stock flies on positive data for tumor-infiltrating lymphocyte technology

LN-145, which treats cervical cancer in patients who have progressed to or past chemotherapy, is one of two Iovance drugs that the Baird analyst believes can submit Biologics License Applications by the end of 2020.

A BLA allows a biologic product to be introduced into interstate commerce.

"Combined with lifileucel in post-PD-1 metastatic melanoma, for which we expect success, we now consider it reasonable that IOVA's TIL platform could have two drugs that are BLA-ready by [the end of 2020]," Kumar wrote.

Both drugs make use of the California-based company’s tumor-infiltrating lymphocyte technology. The other, called lifileucel, is a treatment for metastatic melanoma, a late-stage skin cancer.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Iovance Biotherapeutics

Price: $21.44

Market: NASDAQ
Market Cap: $2.65 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Anglo Pacific Group further increases stake in Labrador Iron...

Anglo Pacific Group PLC's (LON:APF, TSE:APY) Juilian Treger speaks to Proactive London's Andrew Scott following the news they've increased their shareholding in Labrador Iron Ore Royalty Corp (LIORC) to 5.88%. After its latest investment of around C$9.8mln – roughly £5.8mln – it has now...

1 hour, 19 minutes ago

2 min read